4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Epilepsy by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 811 ongoing clinical trials involving Epilepsy
Of the 811 trials,324 trials are in Phase III
Furthermore, 233 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Epilepsy by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Epilepsy, a Central Nervous System disorder. The highest number of ongoing clinical trials involving Epilepsy is in Asia-Pacific. North America and Europe are among some of the other prominent regions involved in Epilepsy-related drug trials.

UCB SA.: The leading ongoing Epilepsy-related clinical trials sponsor

UCB SA, the Belgium-based pharmaceutical company, is the top sponsor for Epilepsy-related ongoing clinical trials.

Eisai Co Ltd, SK Biopharmaceuticals Co Ltd, Zogenix Inc, Xenon Pharmaceuticals Inc, Marinus Pharmaceuticals Inc, and Xuanwu Hospital Capital Medical University are a few other notable sponsors involving Epilepsy.

A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Epilepsy

Lacosamide (Vimpat), Levetiracetam (Keppra, Kepcet, E Keppra), and Corticotropin, Repository Corticotropin (H.P. Acthar/Acthar) are among the key marketed drugs involving Epilepsy.

Lacosamide (Vimpat), a Dihydropyrimidinase Related Protein 2 Inhibitor; Voltage-Gated Sodium Channel (SCN) Blocker, is indicated as adjunctive therapy and monotherapy for the treatment of partial-onset seizures in adults with epilepsy. The drug is marketed globally including in the US, the UK, France, Germany, China, and Japan by several prominent pharma giants including UCB Inc. Lacosamide was first approved in 2008 and formulated as film-coated tablets, coated tablets, and syrup for oral route of administration and solution for intravenous route of administration.

Levetiracetam (Keppra, Kepcet, E Keppra), a Synaptic Vesicle Glycoprotein 2A Binder; Voltage Dependent N-Type Calcium Channel Subunit Alpha 1B Blocker, is indicated for the treatment of epilepsy, generalized seizures, generalized tonic-clonic seizure, myoclonic seizures, partial seizure (including secondary generalized seizure) and also for partial seizures in children. The drug is marketed globally including in the US, the UK, France, Germany, China, and Japan by several prominent pharma giants including UCB Inc. Levetiracetam was first approved in 1999 and formulated as film-coated tablets, solutions for oral administration, and injection solution concentrate for intravenous route of administration.